Evenity (Romosozumab) VA Coverage Pathway

What Evenity Is and Why It Costs So Much

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, Evenity has a dual mechanism: it increases bone formation while simultaneously reducing bone resorption. No other approved osteoporosis drug works this way.

The FDA approved Evenity in April 2019 specifically for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies [1]. The wholesale acquisition cost for a single monthly dose (two 105 mg/1.17 mL prefilled syringes totaling 210 mg) runs approximately $1,825, placing the full 12-month course near $22,000 at cash-pay pricing [2].

The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fractures by 73% compared to placebo at 12 months (0.5% vs. 1.8%, P<0.001) [3]. The ARCH trial (N=4,093) compared romosozumab to alendronate and found a 48% lower risk of new vertebral fractures at 24 months in the romosozumab-to-denosumab sequence group [4]. These fracture reduction numbers are among the largest observed in any osteoporosis trial, which explains why the drug commands premium pricing and why VA providers sometimes pursue access for high-risk patients despite formulary restrictions.

The Endocrine Society's 2019 updated guidelines recommend romosozumab as a first-line option for postmenopausal women with osteoporosis at very high fracture risk, stating that "anabolic therapy should be considered as initial treatment rather than antiresorptive therapy for patients at very high fracture risk" [5]. That recommendation carries weight in VA formulary decisions.

How VA Drug Formulary Decisions Work

The VA National Formulary is managed by the VA Pharmacy Benefits Management (PBM) Services office in coordination with the Medical Advisory Panel (MAP). Drugs on the national formulary are available at all VA Medical Centers without special authorization. Drugs not on the national formulary require additional clinical justification.

Each Veterans Integrated Service Network (VISN) and individual VA Medical Center also operates a local Pharmacy and Therapeutics (P&T) Committee. These committees can add drugs to a local formulary or establish criteria-for-use (CFU) protocols that define which patients qualify for specific medications [6]. Romosozumab falls into this restricted category at most facilities. The practical result: your VA physician can prescribe Evenity, but the prescription triggers a review process before the pharmacy dispenses it.

VA drug pricing differs substantially from commercial pricing. Under the Federal Supply Schedule (FSS) and the Federal Ceiling Price (FCP) mandated by 38 U.S.C. § 8126, the VA negotiates prices that are at minimum 24% below the non-federal average manufacturer price [7]. For biologics like Evenity, the actual negotiated price is not publicly disclosed, but VA acquisition costs are consistently lower than commercial insurance net prices. This cost structure makes VA one of the more favorable pathways for accessing high-cost osteoporosis biologics.

Step-by-Step: Getting Evenity Through the VA

The process has defined stages. Your VA provider initiates the request, not you, but understanding each step helps you prepare documentation and avoid delays.

Step 1: Establish clinical eligibility. Your provider needs to document that you meet criteria for romosozumab use. Typical VA criteria-for-use requirements include a confirmed diagnosis of postmenopausal osteoporosis (T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip on DXA scan), evidence of high or very high fracture risk (prior fragility fracture, FRAX 10-year major osteoporotic fracture probability above 20%, or FRAX hip fracture probability above 3%), and documentation that you have tried or cannot tolerate first-line agents such as alendronate, risedronate, or zoledronic acid [8].

Step 2: Non-formulary drug request (NFDR). Your provider submits a non-formulary drug request through the VA's computerized patient record system (CPRS). This request goes to the facility's P&T Committee or a designated clinical pharmacist reviewer. The request must include your DXA results, fracture history, FRAX score, prior osteoporosis treatment history, and the reason alternatives are insufficient [6].

Step 3: Cardiovascular screening. Because Evenity carries an FDA black box warning for cardiovascular events, VA facilities typically require documentation that the patient has no history of myocardial infarction or stroke within the preceding 12 months. Some facilities require a more recent cardiac risk assessment. The ARCH trial identified a higher rate of major adverse cardiac events in the romosozumab group versus alendronate (2.5% vs. 1.9% at 12 months), which drove the boxed warning [4].

Step 4: P&T Committee review and approval. Review timelines vary by facility. Some VA Medical Centers turn around non-formulary requests within 5 to 7 business days. Others, particularly smaller community-based outpatient clinics (CBOCs) that route through a parent facility, may take 2 to 4 weeks. If denied, your provider can appeal with additional clinical justification.

Step 5: Administration. Evenity is administered as two subcutaneous injections (one in each thigh, abdomen, or upper arm) by a healthcare professional. At the VA, this typically happens at an outpatient infusion clinic or your primary care clinic. You will need 12 monthly visits to complete the full course.

What Veterans Pay Out of Pocket

VA prescription copays depend on your priority group and the nature of your condition. The system is more favorable than most commercial insurance plans for high-cost biologics.

Veterans with service-connected disabilities rated at 50% or higher pay $0 for all VA prescriptions, regardless of whether the medication treats the service-connected condition [9]. Veterans receiving medications for a service-connected condition pay $0 regardless of disability rating. Former prisoners of war, veterans receiving aid and attendance or housebound benefits, and veterans whose annual income falls below the VA means test threshold also qualify for $0 copays.

For all other enrolled veterans, VA outpatient prescription copays are tiered. As of 2026, the copay structure is approximately $5 for a 30-day supply of Tier 1 (preferred generic) medications and $11 for Tier 2 and Tier 3 medications [9]. Because Evenity is administered in a VA clinical setting, it may be billed as an outpatient procedure rather than a dispensed prescription, which can change the cost-sharing calculation. The annual VA copay cap for outpatient medications is $700, meaning that even veterans who pay copays will not exceed this amount in a calendar year.

Compare this to commercial insurance, where patients may face specialty tier coinsurance of 25% to 33%. On a $1,825 monthly drug, that translates to $456 to $602 per injection, or $5,475 to $7,225 annually, before reaching an out-of-pocket maximum [2]. The VA pathway eliminates this exposure for most veterans.

Non-VA Insurance Pathways for Veterans With Dual Coverage

Some veterans carry both VA enrollment and private insurance (through an employer, a spouse's plan, or Medicare). If your private insurer covers Evenity, you can choose to use that benefit instead of or alongside VA care. A few considerations apply.

Most commercial plans and Medicare Part B cover Evenity as a physician-administered injectable under the medical benefit rather than the pharmacy benefit. Medicare Part B covers Evenity at 80% of the Medicare-approved amount after you meet the annual Part B deductible ($257 in 2026), leaving a 20% coinsurance obligation. A Medicare Supplement (Medigap) plan may cover some or all of that 20% [10]. TRICARE, the insurance program for active-duty family members and retirees, covers Evenity under its pharmacy benefit with prior authorization; the specialty copay tier applies.

For veterans using commercial insurance, Amgen's Evenity Complete support program provides copay assistance cards that can reduce out-of-pocket costs to as little as $5 per month for commercially insured patients. This program does not apply to government insurance, meaning it cannot be used with VA, Medicare, Medicaid, or TRICARE coverage [11]. If you have both VA and commercial coverage, using the commercial plan with the copay card for Evenity while using the VA for other medications is a legitimate strategy some veterans employ.

The Amgen Safety Net Foundation and Patient Assistance

For veterans who are not enrolled in VA healthcare or who do not qualify for VA prescription benefits, Amgen operates the Amgen Safety Net Foundation. This program provides Evenity at no cost to patients who meet income eligibility requirements (generally household income at or below 400% of the Federal Poverty Level) and who lack insurance coverage for the drug or have exhausted their insurance benefits [11].

The application requires proof of income, a prescription from a licensed provider, and documentation of insurance status. Processing takes approximately 2 to 4 weeks. The foundation ships the medication directly to the prescribing provider's office for administration.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital, has noted that "the biggest barrier to romosozumab access is not clinical appropriateness but rather the administrative burden of navigating prior authorization and appeals processes" [12]. This observation applies equally to the VA non-formulary process, where thorough upfront documentation significantly reduces the chance of denial or delay.

Sequencing Therapy After the 12-Month Evenity Course

Evenity is approved for only 12 months of continuous use. Bone density gains achieved during romosozumab treatment decline rapidly if no follow-up antiresorptive therapy is started. The FRAME extension study showed that patients who transitioned from romosozumab to denosumab maintained and increased BMD gains through 24 months, while those who received placebo after romosozumab lost a significant portion of their gains [3].

VA formulary access to follow-up agents is generally straightforward. Alendronate and risedronate are on the VA National Formulary as first-line agents. Denosumab (Prolia) is available at most VA facilities through criteria-for-use protocols. Zoledronic acid (Reclast), given as a once-yearly IV infusion, is also accessible through the VA.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend that "patients completing a course of romosozumab should be transitioned to an antiresorptive agent such as denosumab or a bisphosphonate to maintain the BMD gains achieved" [13]. Your VA provider should have a sequencing plan in place before initiating romosozumab. Ask about this at your first appointment.

Tips for a Smooth VA Approval Process

Preparation matters. These specific actions reduce denial rates and processing time.

Bring your complete DXA scan reports (not just the summary) to your VA appointment. If you had DXA scans done outside the VA system, request that copies be sent to your VA provider or upload them through the VA Health Connect portal. Include dates of any prior fractures and imaging confirmation (X-ray, CT, or MRI reports). If you have previously tried bisphosphonates, document the specific drug, dose, duration, and reason for discontinuation (intolerance, GI side effects, atypical fracture concern, or inadequate response defined as new fracture or continued BMD decline on therapy).

Request that your provider calculate your FRAX score and include it in the non-formulary request. A 10-year major osteoporotic fracture probability exceeding 20% or hip fracture probability exceeding 3% strengthens the case for romosozumab over standard antiresorptive therapy [8].

If your initial request is denied, ask your provider to submit a formal appeal. Include any new clinical data, a written clinical rationale, and reference the Endocrine Society or AACE guideline recommendations for anabolic-first therapy in very high-risk patients. VA Patient Advocates at your facility can also assist with navigating the appeals process. The VA Patient Advocate phone line is available through your local VA Medical Center's main number.

Cardiovascular Risk: What the VA Will Screen For

The FDA black box warning on Evenity states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death, and should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [1]. The ARCH trial found that adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over the first 12 months of treatment (risk difference 0.6%) [4].

VA providers will typically order a baseline cardiovascular risk assessment before submitting the non-formulary request. This may include a review of your cardiac history, blood pressure, lipid panel, and potentially an EKG or cardiology consultation if you have existing risk factors. The 2020 ASBMR position statement notes that "the cardiovascular signal in ARCH should be weighed against the substantial fracture reduction benefit, particularly in patients without established cardiovascular disease" [14].

Veterans with a history of MI or stroke within the past year will not qualify for romosozumab through the VA. Those with controlled cardiovascular risk factors (managed hypertension, statin-treated hyperlipidemia) may still be eligible, but expect the review process to include additional cardiovascular documentation.

Your VA provider should schedule follow-up cardiovascular monitoring during the 12-month treatment course. Report any new chest pain, sudden severe headache, vision changes, weakness on one side of the body, or shortness of breath immediately.